Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Aditi Singhai
Alison Sathe
Anders Vinther
Anne-Caroline Boillot
Barbara W. Unger
Barry Price
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Khushboo Agrawal
Mark Agostino
Michael de la Torre
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Tashil Sharma
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.
Enforcement

Review of the Office of Generic Drugs’ 2018 Annual Report

No items found.

MHRA’s “Right Environment”

No items found.
Trends

Analysis of CDER Report on Pharmaceutical Quality

No items found.

How Mindful Leadership Supports Data Integrity

No items found.
Trends

How Small Pharma Firms Can Prepare for a GMP Inspection in 2019

No items found.

Data Integrity Trends in 483s and Warning Letters: Part 3

No items found.
Trends

Data Integrity Trends in 483s and Warning Letters: Part 2

No items found.
Trends

Data Integrity Trends in 483s and Warning Letters: Part 1

No items found.
Press Release

Govzilla and FOI Services Announce Strategic Partnership

No items found.
Enforcement

Why Did McKesson Receive the First DSCSA Warning Letter?

No items found.

FDA Form 483: A Helpful Guide to Proactive Compliance

No items found.
Enforcement

FDA Cites Part 11 in Clinical Trial

No items found.

FINAL Part 3: Who’s Who? Seeing CROs Clearly.

No items found.

Part 2: Who’s Who? Seeing CROs Clearly.

No items found.

Part 1: Who’s Who? Seeing CROs Clearly.

No items found.
Trends

FINAL Part 2: How to Stop the Data Integrity Excuses

No items found.

9 New Recalls | Week of November 4th 2018

No items found.
Conference Spotlight

49 New FDA 483s Added | November 12th 2018

API
Catalyst
Financial Services